Relationship between retinal fluid and visual acuity in patients with exudative age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen: subgroup and post-hoc analyses from the ALTAIR study.
Relationship between retinal fluid and visual acuity in patients with exudative age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen: subgroup and post-hoc analyses from the ALTAIR study.
复制标题
DOI：
10.1007/s00417-021-05293-y
复制
发表时间：
2021-12
期刊：
影响因子：
--
通讯作者：
ALTAIR Investigators
中科院分区：
文献类型：
--
作者：
Ohji M;Okada AA;Sasaki K;Moon SC;Machewitz T;Takahashi K;ALTAIR Investigators
目的：探讨Altair研究中玻璃体内注射阿普利康(IVT-AFL)治疗和延长(T&E)治疗的患者的视网膜液体状态与最佳矫正视力(BCVA)的关系。根据第16周的整体液体状态(预先定义)以及基线时任何液体、视网膜内液体(IRF)、视网膜下液体(SRF)或色素上皮脱离与第16、52和96周(后)之间的关系来调查结果。这些分析包括渗出性老年性黄斑变性的单纯治疗患者(N = 246)，年龄50岁的 ≥ 伴BCVA的73-25例早期治疗糖尿病视网膜病变研究信件，他们参与了Altair研究。16周时无积液和有积液患者术后16周视力平均变化(标准差)分别为 + 10.6(10.9)和 + 6.5(16.0)个字母，至96周时无液体和有液体患者平均视力变化分别为 + 9.1(14.3)和 + 4.3(16.1)个字母。最后一次注射间隔16周的患者分别为33.6%和2.0%(52周)，16周时无液体和有液体患者分别为62.9%和17.6%。基线时，35.7%的患者有IRF和85.2%的患者有SRF，这一比例在16、52和96周分别降至11.8%(IRF)和31.7%(SRF)、8.5%(IRF)和18.7%(SRF)、6.5%(IRF)和20.7%(SRF)。与不存在IRF相比，在所有时间点都存在IRF与较差的BCVA相关，而与不存在SRF相比，存在SRF与较差的BCVA无关。在渗出型 ~ 患者中，无论液体类型如何，IVT-AFL T&E剂量都能有效地清除液体。16周时无液体的患者比16周时有液体的患者有更好的视力。在研究结束时，超过60%的患者在16周时没有液体的患者达到了最大治疗间隔16周，而在16周有液体的患者中 <； 只有20%。ClinicalTrials.gov标识：NCT02305238
To explore the relationship between retinal fluid status and best-corrected visual acuity (BCVA) in patients treated with intravitreal aflibercept (IVT-AFL) treat-and-extend (T&E) in the ALTAIR study. Outcomes were investigated according to overall fluid status at week 16 (predefined) and the relationship between any fluid, intraretinal fluid (IRF), subretinal fluid (SRF), or pigment epithelial detachment with BCVA at baseline, and weeks 16, 52, and 96 (post-hoc). The analyses involved treatment-naïve patients (N = 246) with exudative age-related macular degeneration (AMD), aged ≥ 50 years with BCVA of 73–25 Early Treatment Diabetic Retinopathy Study letters, who participated in the ALTAIR study. The mean (standard deviation) change in BCVA from baseline to week 52 was + 10.6 (10.9) and + 6.5 (16.0) letters in patients without and with fluid at week 16, respectively; and to week 96 was + 9.1 (14.3) and + 4.3 (16.1) letters in patients without and with fluid at week 16, respectively. The last injection interval was 16 weeks in 33.6% and 2.0% (week 52), and 62.9% and 17.6% (week 96) of patients without or with fluid at week 16, respectively. At baseline, 35.7% of patients had IRF and 85.2% of patients had SRF, which decreased to 11.8% (IRF) and 31.7% (SRF) of patients, 8.5% (IRF) and 18.7% (SRF), and 6.5% (IRF) and 20.7% (SRF) at weeks 16, 52, and 96, respectively. Presence of IRF at all timepoints was associated with poorer BCVA than if IRF was absent, while the presence of SRF was not associated with poorer BCVA compared with the absence of SRF. IVT-AFL T&E dosing was effective at clearing fluid regardless of fluid type in ~ 80% of patients with exudative AMD. Patients without fluid at week 16 had numerically better BCVA than those with fluid at week 16. Over 60% of patients without fluid at week 16 achieved the maximum treatment interval of 16 weeks by study end, compared with < 20% of patients with fluid at week 16. IRF (weeks 16, 52, 96), although evident in a small number of patients, was associated with poorer BCVA, whereas SRF was not. ClinicalTrials.gov Identifier: NCT02305238
登录
查看更多内容
影响因子：
4.5
作者：
Matsumoto, Hidetaka;Morimoto, Masahiro;Akiyama, Hideo
通讯作者：
Akiyama, Hideo
影响因子：
13.7
作者：
Jaffe GJ;Ying GS;Toth CA;Daniel E;Grunwald JE;Martin DF;Maguire MG;Comparison of Age-related Macular Degeneration Treatments Trials Research Group
通讯作者：
Comparison of Age-related Macular Degeneration Treatments Trials Research Group
影响因子：
17.8
作者：
Schmidt-Erfurth, Ursula;Waldstein, Sebastian M.
通讯作者：
Waldstein, Sebastian M.
影响因子：
13.7
作者：
Jaffe, Glenn J.;Kaiser, Peter K.;Heier, Jeffrey S.
通讯作者：
Heier, Jeffrey S.
影响因子：
16.2
作者：
Ambati J;Fowler BJ
通讯作者：
Fowler BJ